Therapeutic trial & Research projects

Study Type

Phase

Title

Interventional (prospective) II/III Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Observational (prospective)   Asymptomatic Small Pancreatic Endocrine Neoplasms. (ASPEN)
Observational (prospective/retrospective)   Mantenimento o sospensione della terapia con analoghi della Somatostatina (SSA) dopo progressione di malattia in pazienti con tumori neuroendocrini gastropancreatici di grado 1-2 (GEP NET G1-G2) e toracici (carcinoidi tipici e atipici di polmone e timo) ELIOS STUDY
Observational (retrospective)   Resezione curativa nelle neoplasie neuroendocrine digestive: tasso di sopravvivenza libero da recidiva e definizione di uno score di recidiva
Interventional (prospective) III Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2)
Interventional (prospective) II A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
Interventional (prospective) II Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015)
Observational (prospective)   Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs (REAL-LU)
Observational (prospective/retrospective)   ITANET Registry: Multicenter registry of GEP-NET
Observational (prospective)   Quality of life and sexual function in patients with well differentiated neuroendocrine tumors
Observational (prospective)   Health‑related quality of life in patients with neuroendocrine neoplasms
Observational (retrospective)   Identificazione di predittori molecolari di risposta alla terapia radiorecettoriale in pazienti con GEP-NETs
Observational (prospective)   Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment (FiReNEN)